Ferring and Igenomix Collaborate to Advance Care in Reproductive Medicine and Maternal Health
04 Junio 2020 - 12:00AM
Business Wire
- Collaboration aims to identify novel targets and disease
mechanisms in infertility and pregnancy-related conditions, with
the goal of developing innovative diagnostic and therapeutic
strategies
- As part of the translational research collaboration, a new
research hub will be created in Boston, bringing together
scientists from both companies
- Collaboration combines Ferring’s therapeutic expertise with
Igenomix’s diagnostic capabilities and demonstrates both companies’
commitment to building families worldwide
Ferring Pharmaceuticals and Igenomix today announced a two-year
research collaboration aimed at the discovery of novel targets and
disease mechanisms in infertility and pregnancy-related conditions,
including preeclampsia, with the goal of developing innovative
diagnostic and therapeutic strategies in these areas of high unmet
need.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200603005784/en/
A new research hub will be created in Boston, bringing together
scientists and expertise from both companies. The hub will focus on
investigating molecular signatures, developing novel functional
genomic systems and creating translational tools to study for
embryo implantation, endometrial microbiome interaction and
decidualization biology to drive innovative solutions for
patients.
“Today, 1 in 6 couples worldwide are affected by fertility
issues, with embryo implantation being a critical step to improving
success rates in assisted reproduction technologies (ART) such as
IVF. Furthermore, between 3 and 5% of all pregnancies are affected
by preeclampsia,1 a severe complication which increases the
morbidity and mortality of both mother and baby, said Joan-Carles
Arce, Senior Vice President of Reproductive Medicine and Maternal
Health, Ferring. Through this collaboration, we aim to advance
diagnostic testing and the discovery of candidate drug targets in
these areas of high unmet need and ultimately help more people
build healthy families worldwide.”
“This new research hub will connect Igenomix’s unique diagnostic
capabilities with Ferring’s deep therapeutic expertise, said
Professor Carlos Simón, Head of Scientific Board of Igenomix
Foundation and Project Lead for the new hub. We believe this
collaboration will accelerate scientific findings and improve
conception rates at a time when significant progress is needed in
preimplantation science to help more women and families experience
healthy pregnancies.”
ENDS
About Fertility Issues
The World Health Organization defines infertility as a disease
of the reproductive system defined by the failure to achieve a
clinical pregnancy after 12 months or more of regular unprotected
sexual intercourse. Today, 1 in 6 couples worldwide are affected by
fertility issues. Assisted Reproductive Technologies (ART) such as
In Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection
(ICSI) can help couples who have problems conceiving naturally.
About Preeclampsia
Preeclampsia is a common and severe complication of pregnancy
characterised by high blood pressure and multiple organ failure. It
affects between 3% and 5% of all pregnancies in the US.1 There is a
significant unmet need for an effective treatment for preeclampsia;
currently the only ‘treatment’ is delivery of the baby.
Preeclampsia is responsible for approximately 20% of all preterm
births2 and increases the morbidity and mortality of both mother
and baby, especially in developing countries. An effective
treatment would bring significant improvements in global infant and
maternal health.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group committed to helping people around the
world build families and live better lives. Headquartered in
Saint-Prex, Switzerland, Ferring is a leader in reproductive
medicine and maternal health, and in specialty areas within
gastroenterology and urology. Ferring has been developing
treatments for mothers and babies for over 50 years and has a
portfolio covering treatments from conception to birth. Founded in
1950, privately-owned Ferring now employs approximately 6,500
people worldwide, has its own operating subsidiaries in nearly 60
countries and markets its products in 110 countries.
Learn more at www.ferring.com, or connect with us on Twitter,
Facebook, Instagram, LinkedIn and YouTube.
About Igenomix
Igenomix is a biotech company based in Valencia, Spain,
specialized in reproductive genetics. Its expertise in fertility
and its advanced research capacity situates the company as a
worldwide referent in this area. Igenomix has 23 laboratories
across the world and employs more than 400 professionals. Since the
company launch in 2010, Igenomix has published more than 450
scientific papers and its communications have taken place during
high level congresses such as ESHRE (European Society of Human
Reproduction) or ASRM (American Society for Reproductive Medicine).
Igenomix researchers have received numerous awards recognizing
research and many of them share their knowledge and knowhow in
leading US universities such as Stanford or Harvard.
References:
- CDC High Blood Pressure During Pregnancy 2020. Available at:
https://www.cdc.gov/bloodpressure/pregnancy.htm
- Preeclampsia Foundation. FAQs. 2018. Available at:
https://www.preeclampsia.org/faqs
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200603005784/en/
Bhavin Vaid Head of Corporate Communications +41 58 301
0952 (direct) +41 79 191 0632 (mobile) bhavin.vaid@ferring.com
Lindsey Rodger Senior Manager, Corporate Communications +41
58 451 4023 (direct) +41 79 191 0486 (mobile)
lindsey.rodger@ferring.com Dulce Iborra +34 647 942 875
dulce@laembajadora.es